These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 30500673)

  • 1. Effect of P2Y
    Spinthakis N; Farag M; Gue YX; Srinivasan M; Wellsted DM; Gorog DA
    Thromb Res; 2019 Jan; 173():102-108. PubMed ID: 30500673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
    Stratz C; Nührenberg T; Valina CM; Löffelhardt N; Mashayekhi K; Ferenc M; Trenk D; Neumann FJ; Hochholzer W
    Thromb Haemost; 2018 Feb; 118(2):362-368. PubMed ID: 29443372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of ticagrelor and aspirin versus clopidogrel and aspirin in symptomatic patients with peripheral arterial disease: Thrombus burden assessed by optical coherence tomography.
    Yang X; Leesar MA; Ahmed H; Lendel V; Rodriguez G; Mutlu D; Cawich I; Prasad A; Oglesby M; Marmagkiolis K; Phillips NE; Jouke D; Michalek J; Liu Q; Milner T; McElroy A; Hoyt T; Feldman MD; Cilingiroglu M
    Cardiovasc Revasc Med; 2018 Oct; 19(7 Pt A):778-784. PubMed ID: 29550045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
    Ravnefjord A; Weilitz J; Emanuelsson BM; van Giezen JJ
    Thromb Res; 2012 Oct; 130(4):622-8. PubMed ID: 22909827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
    Schneider DJ; Agarwal Z; Seecheran N; Keating FK; Gogo P
    JACC Cardiovasc Interv; 2014 Apr; 7(4):435-42. PubMed ID: 24656538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of very low dose rivaroxaban in addition to dual antiplatelet therapy on endogenous fibrinolysis in acute coronary syndrome: The VaLiDate-R study.
    Gue YX; Memtsas V; Kanji R; Wellsted DM; Busby A; Smith M; Vilar E; Ryding A; Arachchillage DJ; Gorog DA
    Thromb Res; 2024 Apr; 236():144-154. PubMed ID: 38447421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of data on cangrelor.
    Qamar A; Bhatt DL
    Pharmacol Ther; 2016 Mar; 159():102-9. PubMed ID: 26802900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
    Thomas MR; Outteridge SN; Ajjan RA; Phoenix F; Sangha GK; Faulkner RE; Ecob R; Judge HM; Khan H; West LE; Dockrell DH; Sabroe I; Storey RF
    Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2562-70. PubMed ID: 26515417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Case Report of Cangrelor Bridge Therapy for a Diagnostic Bronchoscopy With Biopsy.
    Calnan MW; Crawford AN
    J Pharm Pract; 2020 Apr; 33(2):231-235. PubMed ID: 30139291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
    Waite LH; Phan YL; Spinler SA
    Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
    Rollini F; Franchi F; Tello-Montoliu A; Patel R; Darlington A; Ferreiro JL; Cho JR; Muñiz-Lozano A; Desai B; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2014 Apr; 7(4):426-34. PubMed ID: 24630878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombus remodelling by reversible and irreversible P2Y
    Tunströmer K; Faxälv L; Larsson P; Lindahl TL; Boknäs N
    Platelets; 2023 Dec; 34(1):2157805. PubMed ID: 36631918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction.
    Mohammad MA; Andell P; Koul S; James S; Scherstén F; Götberg M; Erlinge D
    Platelets; 2017 Jun; 28(4):414-416. PubMed ID: 27885888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?
    Alexopoulos D; Katogiannis K; Sfantou D; Lekakis J
    Platelets; 2018 May; 29(3):228-237. PubMed ID: 29022423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists.
    Schneider DJ
    Coron Artery Dis; 2016 Jan; 27(1):65-9. PubMed ID: 26444255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Course of platelet miRNAs after cessation of P2Y12 antagonists.
    Jäger B; Stojkovic S; Haller PM; Piackova E; Kahl BS; Andric T; Vargas KG; Wojta J; Huber K
    Eur J Clin Invest; 2019 Aug; 49(8):e13149. PubMed ID: 31172515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases.
    Tao L; Ren S; Zhang L; Liu W; Zhao Y; Chen C; Mao X; Chen Z; Gu X
    Med Sci Monit; 2022 May; 28():e935664. PubMed ID: 35570383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan.
    Chen YC; Lin FY; Lin YW; Cheng SM; Lin RH; Chuang CL; Sheu JS; Chen SM; Chang CC; Tsai CS
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):75-86. PubMed ID: 30467686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.